

Path to commercialization! The implementation journey

Location : Westin Ottawa (11 Colonel By Dr, Ottawa, ON K1N 9H4)

Date: February 8th and 9th, 2024

In partnership with:



Thursday, February 8th, 2024 – 11:30-22:00

Welcome (11:30-13:00)

- Meet and great (11:30-12:00)
- Lunch (Annual General Meeting (12:00-12:45))
- Major sponsor presentation: Fasken (12:45-13:00)

Westin Ottawa (Room TBD)

Regulatory (13:00-13:45)

505(b)2 regulatory pathway; what is the Canadian alternative?




*Katharine Manson (Intrinsic)
VP of Regulatory Affairs*

Legal (14:00-14:45)

The clauses you didn't read but you should have...indemnity.

- *Why is indemnity so important?*
- *How to negotiate indemnity?*



*Cheryl Reicin (Mintz)
Partner / International Chair, Life Sciences*

Market access (15:30-16:15)

Innovation and the winds of change

- *How can Post-Market Drug Evaluation (PMDE) Program (CADTH) support industry?*
- *Real World Evidence (RWE); an underestimated and powerful ally to commercialization.*




*Heather Logan (CADTH)
VP Strategic Initiatives and Relations*

Commercial (16:30-17:15)

From theoretical to factual forecast, not all forecasts are created equally.

- *How do we bridge the gap between BD forecast and commercial operationalization?*
- *Are BD forecasts too sugar-coated for commercial?*



*Brigitte Léonard, Ph.D. (Heal Canada)
Chief Scientific Officer*




Winterlude: Skating/walking on Rideau canal (weather permit, 17:30-19:00)

<https://ncc-ccn.gc.ca/places/rideau-canal-skateway>

Networking cocktail (19:00-20:00)

Dinner: Keynote Speaker (20:00-22:00)

Bringing innovative medicines to Canada. How is Health Canada supporting the biotech & pharmaceutical industries?



*Pamela Aung-Thin (Health Canada)
(Assistant Deputy Minister, Health Products and Food Branch)*

LSPC Awards

- Hall of Fame and Deal of the Year


Path to commercialization! The implementation journey

Friday, February 9th, 2024 – 7:00-14:00

Executive Leadership Teams: (8:30-9:15)

AI in pharma; not a futuristic concept anymore.

- *Current Pharmaceutical Challenges and the Role of AI*
- *Different supervised and unsupervised AI learning models/tools for pharmaceutical applications.*
 - *Drug Discovery and Design, Predictive Maintenance and Quality Control, Drug Target Identification, Disease Diagnosis and Prognosis, Adverse Event Detection, and Predictive Modeling for Clinical Trials*




*Dr Laurent Tillement, Ph.D. (MIA)
Specialist in building partnerships and networking within the Canadian biopharmaceutical and AI industries*

Finance: (9:30-10:15)

Funding in Canada; the truth about the unturned rocks.

- *Have we exhausted all resources for accelerating research and innovation projects in Canada?*
- *Getting funding from FDA and EMA in Canada; myth or reality?*



*Laurent Lecanu, Ph.D. (Leyton Canada)
Business Development Manager*

Commercial: (10:45-11:30)

The challenges of introducing medical devices to Canada.

- *MDSAP why is Canada the only country enforcing it, and would others follow through?*



*Louis-Paul Marin Eng., LL.B., LL.M (LOK North America)
President and Founder*


Market access (11:45-12:30)

Managing the cost of Canadian medicine; Where does the control really lie?

- *Is PMPRB there to haunt or hunt us? What are the impacts of all legal litigations and where will it leave the industry?*
- *Is dropping the patent a crazy idea or a great strategy?*
- *Where does Canada stand five years into the pCPA–CGPA generics pricing initiative?*



*John-Paul Dowson (PDCI Market Access)
Director, Strategic Consulting*



*Jennifer Mathews (PDCI Market Access)
Manager Pricing Strategy*

LSP Canada lunch and connection (12:30-14:00)

Take the time to connect with colleagues and speakers and meet our sponsors



Everyone

Thank you to our Sponsors



FASKEN



cencora